About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

Unimed Pharmaceuticals LLC et al. v. Perrigo Co. et al.
1:14-cv-01004; filed July 31, 2014 in the District Court of Delaware

• Plaintiffs:  Unimed Pharmaceuticals LLC; Besins Healthcare Luxemborg SARL
• Defendants:  Perrigo Co.; Perrigo Israel Pharmaceuticals Ltd.

Unimed Pharmaceuticals LLC et al. v. Watson Laboratories Inc.
1:14-cv-01003; filed July 31, 2014 in the District Court of Delaware

• Plaintiffs:  Unimed Pharmaceuticals LLC; Besins Healthcare Luxemborg SARL
• Defendant:  Watson Laboratories Inc.

The complaints in these cases are substantially identical.  Infringement of U.S. Patent Nos. 8,729,057 ("Testosterone Gel and Method of Use," issued May 20, 2014), 8,741,881 (same title, issued June 3, 2014), 8,754,070 (same title, issued June 17, 2014), and 8,759,329 (same title, issued June 24, 2014) following a Paragraph IV certification as part of defendants' filing of an ANDA to manufacture a generic version of AbbVie's AndroGel® (testosterone gel, used to treat conditions associated with a deficiency or absence of endogenous testosterone).  View the Perrigo complaint here.

Astrazeneca AB et al. v. Zydus Pharmaceuticals (USA) Inc. et al.
3:14-cv-04782; filed July 31, 2014 in the District Court of New Jersey

• Plaintiffs:  Astrazeneca AB; Aktiebolaget Hassle; Astrazeneca LP; KBI Inc.; KBI-E Inc.
• Defendants:  Zydus Pharmaceuticals (USA) Inc.; Cadila Healthcare Ltd.

Infringement of U.S. Patent Nos. 6,369,085 ("Form of S-omeprazole," issued April 9, 2002), 7,411,070 (same title, issued August 12, 2008), and 8,466,175 (same title, issued June 18, 2013) following a Paragraph IV certification as part of Zydus' filing of an ANDA to manufacture a generic version of AstraZeneca's Nexium® (esomeprazole magnesium, used for the treatment of gastroesophageal reflux disease).  View the complaint here.

Warner Chilcott Co. LLC et al. v. Apotex Inc. et al.
1:14-cv-00998; filed July 30, 2014 in the District Court of Delaware

• Plaintiffs:  Warner Chilcott Co. LLC; Warner Chilcott (US) LLC
• Defendants:  Apotex Inc.; Apotex Corp.

Infringement of U.S. Patent No. 6,106,864 ("Pharmaceutical Formulations Containing Darifenacin," issued August 22, 2000) following a Paragraph IV certification as part of Apotex's filing of an ANDA to manufacture a generic version of Warner Chilcott's Enablex® (darifenacin, used to treat symptoms of overactive bladder).  View the complaint here.

Impax Laboratories Inc. et al. v. Lannett Holdings Inc. et al.
1:14-cv-00999; filed July 30, 2014 in the District Court of Delaware

• Plaintiffs:  Impax Laboratories Inc.; AstraZeneca AB; AstraZeneca UK Ltd.
• Defendants:  Lannett Holdings Inc.; Lannett Co. Inc.

Infringement of U.S. Patent Nos. 6,750,237 ("Pharmaceutical Formulations Containing Aolmitriptan," issued June 15, 2004) and 7,220,767 (same title, issued May 22, 2007), licensed to Impax, following a Paragraph IV certification as part of Lannett's filing of an ANDA to manufacture a generic version of Impax's Zomig® Nasal Spray (zolmitriptan nasal spray, used for the acute treatment of migraine with or without aura in adults).  View the complaint here.

Taro Pharmaceuticals U.S.A. Inc. et al. v. Perrigo Israel Pharmaceuticals, Ltd.
1:14-cv-00809; filed July 30, 2014 in the Western District of Michigan

• Plaintiffs:  Taro Pharmaceuticals U.S.A. Inc.; Taro Pharmaceuticals North America, Inc.
• Defendant:  Perrigo Israel Pharmaceuticals, Ltd.

Infringement of U.S. Patent Nos. 8,277,780 ("Stable Liquid Desoximetasone Compositions with Reduced Oxidized Impurity" issued October 2, 2012) and 8,715,624 (same title, issued May 6, 2014) following a Paragraph IV certification as part of Perrigo's filing of an ANDA to manufacture a generic version of Taro's Topicort® (desoximetasone topical spray, used for the treatment of plaque psoriasis).  View the complaint here.

Boehringer Ingelheim Pharma GmbH & Co. KG et al. v. Amneal Pharmaceuticals LLC
1:14-cv-04726; filed July 30, 2014 in the District Court of New Jersey

• Plaintiffs:  Boehringer Ingelheim Pharma GmbH & Co. KG; Boehringer Ingelheim International GmbH; Boehringer Ingelheim Pharmaceuticals, Inc.
• Defendant:  Amneal Pharmaceuticals LLC

Boehringer Ingelheim Pharma GmbH & Co. KG et al. v. Mylan Pharmaceuticals Inc.
1:14-cv-04727; filed July 30, 2014 in the District Court of New Jersey

• Plaintiffs:  Boehringer Ingelheim Pharma GmbH & Co. KG; Boehringer Ingelheim International GmbH; Boehringer Ingelheim Pharmaceuticals, Inc.
• Defendant:  Mylan Pharmaceuticals Inc.

The complaints in these cases are substantially identical.  Infringement of U.S. Patent No. 6,015,577 ("Pharmaceutical Compositions Containing Dipyridamole or Mopidamol and Acetylsalicylic Acid or the Physiologically Acceptable Salts Thereof, Processes for Preparing Them and Their Use in Treating Clot Formation," issued January 18, 2000) following a Paragraph IV certification as part of defendants' filing of an ANDA to manufacture a generic version of Boehringer's Aggrenox® (extended-release dipyridamole/acetylsalicylic acid, used to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis).  View the Amneal complaint here.